Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents

Timo Vesikari; Samantha Munson; Robert E. O'Neill; Laura J. York; John L. Perez; Lars Ostergaard; Johannes Beeslaar; Judith Absalon; Joseph J. Eiden; Kathrin U. Jansen; Thomas R. Jones; Shannon L. Harris; Roger Maansson

doi:10.1016/j.vaccine.2018.11.073

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents

Timo Vesikari
, Samantha Munson
, Robert E. O'Neill
, Laura J. York
, John L. Perez
, Lars Ostergaard
, Johannes Beeslaar
, Judith Absalon
, Joseph J. Eiden
, Kathrin U. Jansen
, Thomas R. Jones
, Shannon L. Harris
, Roger Maansson

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

32 Sitaatiot (Scopus)

Alkuperäiskieli	Englanti
Sivut	1710-1719
Julkaisu	Vaccine
Vuosikerta	37
Numero	12
DOI - pysyväislinkit	https://doi.org/10.1016/j.vaccine.2018.11.073
Tila	Julkaistu - 2019
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

SDG 3 – Hyvä terveys ja hyvinvointi

Tutkimusalat

Adolescents
Booster
Meningococcal disease
Persistence
Serogroup B
Vaccine

Julkaisufoorumi-taso

Jufo-taso 1

Pääsy asiakirjaan

10.1016/j.vaccine.2018.11.073

Siteeraa tätä

Vesikari, T., Munson, S., O'Neill, R. E., York, L. J., Perez, J. L., Ostergaard, L., Beeslaar, J., Absalon, J., Eiden, J. J., Jansen, K. U., Jones, T. R., Harris, S. L., & Maansson, R. (2019). Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents. Vaccine, 37(12), 1710-1719. https://doi.org/10.1016/j.vaccine.2018.11.073

@article{b0fd4a9d0d1945558910f93bd68005e6,

title = "Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents",

keywords = "Adolescents, Booster, Meningococcal disease, Persistence, Serogroup B, Vaccine, Adolescents, Booster, Meningococcal disease, Persistence, Serogroup B, Vaccine",

author = "Timo Vesikari and Samantha Munson and O'Neill, \{Robert E.\} and York, \{Laura J.\} and Perez, \{John L.\} and Lars Ostergaard and Johannes Beeslaar and Judith Absalon and Eiden, \{Joseph J.\} and Jansen, \{Kathrin U.\} and Jones, \{Thomas R.\} and Harris, \{Shannon L.\} and Roger Maansson",

year = "2019",

doi = "10.1016/j.vaccine.2018.11.073",

language = "English",

volume = "37",

pages = "1710--1719",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Limited",

number = "12",

}

Vesikari, T, Munson, S, O'Neill, RE, York, LJ, Perez, JL, Ostergaard, L, Beeslaar, J, Absalon, J, Eiden, JJ, Jansen, KU, Jones, TR, Harris, SL & Maansson, R 2019, 'Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents', Vaccine, Vuosikerta 37, Nro 12, Sivut 1710-1719. https://doi.org/10.1016/j.vaccine.2018.11.073

TY - JOUR

T1 - Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension I Cheek for updates study in adolescents

AU - Vesikari, Timo

AU - Munson, Samantha

AU - O'Neill, Robert E.

AU - York, Laura J.

AU - Perez, John L.

AU - Ostergaard, Lars

AU - Beeslaar, Johannes

AU - Absalon, Judith

AU - Eiden, Joseph J.

AU - Jansen, Kathrin U.

AU - Jones, Thomas R.

AU - Harris, Shannon L.

AU - Maansson, Roger

PY - 2019

Y1 - 2019

KW - Adolescents

KW - Booster

KW - Meningococcal disease

KW - Persistence

KW - Serogroup B

KW - Vaccine

KW - Adolescents

KW - Booster

KW - Meningococcal disease

KW - Persistence

KW - Serogroup B

KW - Vaccine

U2 - 10.1016/j.vaccine.2018.11.073

DO - 10.1016/j.vaccine.2018.11.073

M3 - Article

SN - 0264-410X

VL - 37

SP - 1710

EP - 1719

JO - Vaccine

JF - Vaccine

IS - 12

ER -